Insider Transactions Reported by 9 Insiders of Unicycive Therapeutics, Inc.

Symbol
UNCY on Nasdaq
Location
Los Altos, CA

There are no Buy or Sell transactions made by insiders since 18 Mar 2025

Unicycive Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Gaurav Aggarwal Director $8,430,499 25 Aug 2025
Pramod Gupta EVP, Pharmaceuticals and BD 28 Jul 2025
Shalabh K. Gupta CEO, Director 28 Jul 2025
John L. Ryan Director 05 Sep 2023
Sara Kenkare-Mitra Director 28 Jul 2025
John Townsend Chief Financial Officer 28 Jul 2025
Douglas Jermasek EVP of Corporate Strategy 28 Jul 2025
Brigitte Schiller Director 15 Jul 2022
Sandeep Laumas Director 28 Jul 2025

Recent Insider Transactions by Companies or Individuals for Unicycive Therapeutics, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Gaurav Aggarwal UNCY Common Stock Conversion of derivative security 57.4% 652,900 1,789,915 25 Aug 2025 By Vivo Opportunity Fund Holdings L.P.
Gaurav Aggarwal UNCY Series A-2 Prime Preferred Stock Disposed to Issuer -100% -3,199 0 25 Aug 2025 By Vivo Opportunity Fund Holdings L.P.
Gaurav Aggarwal UNCY Stock Options Award 117.8% 21,200 39,200 28 Jul 2025 Direct
Sandeep Laumas UNCY Stock Options Award 105.6% 21,200 41,286 28 Jul 2025 Direct
Sara Kenkare-Mitra UNCY Stock Options Award 117.8% 21,200 39,200 28 Jul 2025 Direct
Shalabh K. Gupta UNCY Stock Options Award 50.5% 325,000 968,951 28 Jul 2025 Direct
John Townsend UNCY Stock Options Award 10.9% 10,000 101,557 28 Jul 2025 Direct
Pramod Gupta UNCY Stock Options Award 42.5% 90,000 301,986 28 Jul 2025 Direct
Douglas Jermasek UNCY Stock Options Award 4.87% 10,000 215,500 28 Jul 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.